Actinic Keratosis Treatment Market To Reach $10.13 Billion By 2033

April 2026 | Report Format: Electronic (PDF)

Actinic Keratosis Treatment Market Growth & Trends

The global actinic keratosis treatment market size is expected to reach USD 10.13 billion by 2033, registering a CAGR of 4.86% from 2026 to 2033, according to a new report by Grand View Research, Inc. The market is expected to witness growth opportunities owing to factors such as the wide availability of actinic keratosis therapeutics, rising awareness about the disease, and the rise in AK treatment. Moreover, the increasing prevalence of actinic keratosis and the rising geriatric population across the globe are expected to fuel the market growth during the forecast period.

Invasive squamous cell carcinoma may develop from AK when it becomes malignant (iSCC). Despite the fact that there are a number of potential causes for iSCC, AK is one of the most frequent ones. Additionally, basal cell carcinoma and non-melanoma skin cancer could result from AK. As a result, the demand for AK products across sales channels is being driven by the early diagnosis and treatment of actinic keratosis as a preventive strategy for comorbidities.

In addition, future pipeline medications and the increased use of combination therapy are key market drivers. For instance, Almirall, S.A. has Klisyri (extended label) in phase III of R&D. Furthermore, a rise in the acceptance and commercialization of innovative drugs is another factor that is predicted to fuel market growth. Moreover, increased R&D activities are expected to accelerate the approval of novel drugs used in the treatment of actinic keratosis, hence, propelling the growth over the forecast period.

Key players are adopting strategic initiatives such as product launches, partnerships, and expansion strategies to increase their market share across the globe. For instance, in June 2022, BIOFRONTERA AG announced that its license and marketing authorization holder Louis Widmer SA based in Switzerland has received an extension of its marketing authorization for the management of actinic keratosis in the trunk, extremities, and neck with Ameluz. Moreover, in July 2020, BIOFRONTERA AG announced that it has signed an agreement with Galenica AB for the marketing of BF-RhodoLED and Ameluz in Norway, Finland, Norway, and Iceland.

key Request a free sample copy or view report summary: Actinic Keratosis Treatment Market Report

Actinic Keratosis Treatment Market Report Highlights

Based on therapy topical treatment segment held the largest share of 46.98% in 2025, largely because it offers a convenient, non-invasive approach that can be applied directly to sun-damaged skin areas.
Based on drug class the immune response modifiers segment held the largest revenue share of 35.02% in 2025, as it utilizes the body’s own immune system to identify and eliminate abnormal precancerous cells.
The North American actinic keratosis treatment market held the largest revenue share of 41.41% in 2025 due to the rising awareness among people about actinic keratosis, availability of robust treatment options, and improvements in healthcare infrastructure